ABBV Earnings Preview: Options Price a ±4.0% Move
· The NYC Memo · ABBV reports 2026-10-30
AbbVie Inc. reports October 30, 2026. The October 30, 2026 straddle implies ±3.97% against a 2.85% average reaction, with dealers long gamma and max pain at $280.
Live updates
Oct 30 — Ahead of October 30, 2026 earnings, ABBV spot rose from $285.99 to $290.79 as at-the-money implied volatility increased from 71.6% to 225.1%, implying an earnings move of 3.97%.
Oct 29 — Ahead of ABBV earnings on October 30, 2026, at-the-money implied volatility dropped from 90.6% to 71.6% as net dealer gamma shifted from $-0mn to $4mn, implying reduced volatility expectations and dealer inventory that buffers price action around the 4.22% implied move.
Oct 28 — Ahead of October 30, 2026 earnings, AbbVie's implied move compressed from ±4.78% to ±4.19%, implying a narrower expected price reaction around the $286.39 spot price even as implied volatility climbed from 53.3% to 90.6%.
AbbVie Inc. reports Q3 2026 earnings on October 30, 2026, before open. Spot trades at $290.79, which is -0.6% from its 52-week high after gaining +11.2% over the past month. For the October 30, 2026 expiry, the $11.54 straddle prices an implied move of 3.97% and an implied range of $279.25 to $302.33, with ATM IV at 225.1%. The options market demands more than the historical record. Across 7 prints counted, the average realised reaction is 2.85%, with shares closing higher 1 time and lower 6 times.
Dealers maintain a long gamma lean, which dampens tape volatility into the print. With put/call OI at 0.94, max pain sits at $280.
What the market will be watching
The desk focuses on sales demand for Skyrizi and Rinvoq to confirm replacement of lost Humira revenue. Operating margins will reflect elevated research expenses and promotional spending across the oncology portfolio. Options traders will watch full-year guidance updates for directional signals on cash flow generation. The desk also tracks demand stabilization within the medical aesthetics franchise, specifically Botox. Sustained organic expansion in the newer immunology block remains the essential catalyst for forward price action.
What the options market is pricing
| Measure | Level |
|---|---|
| October 30, 2026, Before Open | |
| Expiry used | October 30, 2026 (0 days out) |
| Spot | $290.79 |
| ATM straddle | $11.54 |
| Implied move | ±3.97% ($279.25 to $302.33) |
| ATM implied vol | 225.1% |
| Put/call open interest | 0.94 |
| Max pain | $280 |
| Net dealer gamma | +$8mn per 1% move, LONG GAMMA |
| Heaviest call strike above spot | $300 (564 contracts) |
| Heaviest put strike below spot | $260 (615 contracts) |
| Street EPS estimate | $3.83 |
| Street revenue estimate | $17.66bn |
Dealers sit long gamma into the print, which means their hedging leans against the move and tends to compress ABBV between catalysts. That damping disappears the moment the number crosses the tape.
How the stock has reacted before
| Report | Next-day move |
|---|---|
| Q2 2026, Jul 6 | -0.04% |
| Q1 2026, Apr 29 | +3.14% |
| Q4 2025, Jan 7 | -3.98% |
| Q3 2025, Oct 31 | -4.45% |
| Q1 2025, Jul 3 | -0.77% |
| Q4 2024, Apr 3 | -7.28% |
| Q4 2024, Jan 6 | -0.32% |
Across the last 7 prints the average absolute reaction is 2.85%, with 1 higher and 6 lower. The best was +3.14% and the worst -7.28%. Options are asking ±3.97%, which is 1.12 points richer than the realised average, the premium seller's case.
Where the stock is trading
| Measure | Level |
|---|---|
| Spot | $290.79 |
| 52-week range | $190.75 to $292.67 |
| Position in that range | 98% |
| From the 52-week high | -0.6% |
| From the 52-week low | +52.5% |
| Past week | +2.0% |
| Past month | +11.2% |
| Past three months | +15.9% |
| 50-day average | $268.63 |
| 200-day average | $236.73 |
Unusual open interest
| Contract | Open interest | Signal |
|---|---|---|
| $260 put, Oct 30 | 599 contracts | oi zscore, 8.1 sigma |
| $120 put, Dec 18 | 197 contracts | vol oi, 7.7 sigma |
| $135 put, Dec 18 | 344 contracts | vol oi, 6.9 sigma |
| $135 put, Dec 18 | 421 contracts | vol oi, 2.5 sigma |
Those are the strikes where positioning built fastest relative to their own history. They mark the levels the tape is most likely to defend or chase after the print.
How the options market is pricing it
The October 30, 2026 straddle marks $279.25 to $302.33 as the range the options market is paying for into the print, with ATM implied vol at 225% set to drain the morning after. A reaction inside that band hands the edge to premium sellers; a break outside it rewards premium buyers. Historically ABBV has moved 2.85% on earnings against the ±3.97% now implied, so the market is pricing this print richer than the recent average. Which side of that trade is right depends on the number, the guidance and where positioning unwinds.
Read the mechanics behind the crush in our earnings volatility guide, and pull the live memo for ABBV before the print.
Data as of October 30, 2026 from the live option chain, exchange price history and SEC-dated earnings reactions. This is research, not investment advice.
Related: ABBV options memo